# Exisulind Versus Placebo After Surgical Removal of the Prostate

> **NCT00166426** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 240 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Exisulind

## Key facts

- **NCT ID:** NCT00166426
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2007-05
- **Final completion:** 2008-05
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2009-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00166426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00166426, "Exisulind Versus Placebo After Surgical Removal of the Prostate". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00166426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*